source
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.BioPharma Dive · 2mo ago↗ source
- The Type of Fat—Not the Amount—Fuels Pancreatic CancerResearch from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.onclive · 2mo ago↗ source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 2mo ago↗ source